Celltrion said it has successfully won bids to supply three key biopharmaceutical products—Remsima (ingredient: infliximab), Herzuma (ingredient: trastuzumab), and Vegzelma (ingredient: bevacizumab)—to Union des Hôpitaux pour les Achats (UniHA), France's largest pharmaceutical procurement group.

Remsima is a Remicade biosimilar for treating autoimmune diseases, Herzuma is a Herceptin biosimilar for treating breast and gastric cancer, and Vegzelma is an Avastin biosimilar for treating colorectal cancer and non-small cell lung cancer.

UniHA, a consortium of major university hospitals, holds significant influence in the French medical industry, controlling approximately 30 percent of the infliximab market, 27 percent of the bevacizumab market, and 13 percent of the trastuzumab market.

As a result of this bid, Celltrion will be the exclusive supplier of these three products until June 2027.

Additionally, Celltrion has secured contracts through the Bretagne procurement group, one of France's regional public hospital networks for Herzuma and Vegzelma. The company will supply its product for four years until June 2028.

Celltrion stressed that it was able to enter such agreements by strategically focusing on building strong relationships with key stakeholders in France's hospital-centric pharmaceutical supply system.

"By closely understanding and addressing the needs highlighted during the bidding process, Celltrion emphasized the strengths of its products, achievements in ESG (Environmental, Social, and Governance) practices, and supply stability to enhance trust in its corporate and product brands," the company said.

Aside from the three biosimilars, Celltrion's infliximab subcutaneous injection, Remsima SC, also showed promising results, achieving a 26 percent market share in the fourth quarter of last year. Combined with Remsima, the Remsima product line captured a 76 percent market share, firmly establishing itself as the leading treatment in France's infliximab market.

Looking ahead, the company stressed that it plans to expand its participation in the French bidding market to sustain its growth momentum.

The company aims to strengthen its sales capabilities for newly approved products such as the Xolair biosimilar Omviclone (ingredient: omalizumab) and the Stelara biosimilar CT-P43 (ingredient: ustekinumab), following recent approval from the European Medicines Agency (EMA).

"By forming favorable networks and enhancing tailored sales activities targeting major French bidding markets, we have steadily expanded our bid-winning achievements across all product lines, from autoimmune treatments to cancer drugs," Celltrion France Office Head Kim Dong-kyu said. "We will aggressively participate in upcoming bids this year and strive for outstanding results with our pipeline products to ensure that more patients can benefit from Celltrion's treatments."